Adaptimmune Therapeutics plc (473A) — Cash Flow-to-Debt Ratio
Adaptimmune Therapeutics plc (473A) has a Cash Flow-to-Debt Ratio of -0.17x as of June 2025, meaning its operating cash flow of €-34.78 Million could theoretically repay 0% of its total liabilities (€201.59 Million) in one year. See 473A free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Adaptimmune Therapeutics plc Cash Flow-to-Debt Ratio (2016–2024)
Historical debt coverage capacity for Adaptimmune Therapeutics plc across 9 annual periods. Also explore 473A shareholders equity momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Adaptimmune Therapeutics plc (2016–2024)
Year-by-year debt coverage analysis for Adaptimmune Therapeutics plc. For market capitalisation and broader financial context, see Adaptimmune Therapeutics plc stock valuation.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.31x | €-73.21 Million | €234.11 Million | ▲ +46.0% |
| 2023 | -0.58x | €-140.88 Million | €243.10 Million | ▼ -1.0% |
| 2022 | -0.57x | €-141.77 Million | €247.04 Million | ▼ -1509.9% |
| 2021 | 0.04x | €10.73 Million | €263.58 Million | ▲ +108.3% |
| 2020 | -0.49x | €-53.59 Million | €109.92 Million | ▲ +74.9% |
| 2019 | -1.94x | €-112.51 Million | €57.91 Million | ▲ +44.4% |
| 2018 | -3.50x | €-104.39 Million | €29.85 Million | ▼ -403.2% |
| 2017 | -0.69x | €-54.31 Million | €78.16 Million | ▲ +1.4% |
| 2016 | -0.70x | €-48.17 Million | €68.37 Million | — |